Inhibition of cyclin E1 by CDK2 inhibitors abolishes the transcription of Mcl-1, and sensitizes HCC cells to regorafenib and sorafenib induced apoptosis (Additional file 5: Figure S5). This evidence concerns the gene CDK2 and hepatocellular carcinoma.